-
Subject Areas on Research
-
A Planar Culture Model of Human Absorptive Enterocytes Reveals Metformin Increases Fatty Acid Oxidation and Export.
-
A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative.
-
A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
-
Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.
-
Antidiabetic therapies affect risk of pancreatic cancer.
-
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
-
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
-
Baseline characteristics of participants in the Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program.
-
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
-
CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice.
-
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
-
Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas.
-
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
-
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.
-
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.
-
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
-
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
-
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
-
Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
-
Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.
-
Current practices in gestational diabetes mellitus diagnosis and management in the United States: survey of maternal-fetal medicine specialists.
-
Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
-
Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.
-
Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes.
-
Editor's Highlight: Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction.
-
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial.
-
Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism.
-
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
-
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
-
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
-
Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
-
Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
-
Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial.
-
Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome.
-
Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial.
-
Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome.
-
Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.
-
Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
-
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
-
Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.
-
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
-
Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.
-
Intercourse compliance, ovulation, and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial.
-
LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.
-
Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin.
-
Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.
-
Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial.
-
Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans.
-
Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
-
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes.
-
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
-
Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer.
-
Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes.
-
Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome.
-
Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis.
-
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
-
Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer.
-
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
-
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.
-
Metformin is associated with improved survival in endometrial cancer.
-
Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
-
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
-
Metformin use and risk of prostate cancer: results from the REDUCE study.
-
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.
-
Metformin use is associated with better survival of diabetic patients with pancreatic cancer.
-
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Response.
-
Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.
-
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.
-
Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas.
-
New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
-
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.
-
Obesity and altered angiogenic-related gene expression in endometrial cancer.
-
One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
-
Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.
-
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.
-
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
-
Pharmacologic Treatment of Diabetes in Pregnancy.
-
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
-
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
-
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
-
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
-
Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction.
-
Repositioning metformin for cancer prevention and treatment.
-
Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers.
-
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
-
Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial.
-
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
-
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
-
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.
-
Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.
-
Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model.
-
Targeting T cell (oxidative) metabolism to improve immunity to viral infection in the context of obesity.
-
Targeting T-cell oxidative metabolism to improve influenza survival in a mouse model of obesity.
-
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects.
-
The clinical treatment of childhood obesity.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
-
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
-
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.